1.. INTRODUCTION
================

In 2005, renal cell carcinoma ([rcc]{.smallcaps}) was the ninth most common cancer in Canada, with an incidence of 1 per 10,000 population [@b1-co16-s1-s45], and in that year, the disease was responsible for 2% of the total cost of cancer (\$17 billion) [@b2-co16-s1-s45]. Until recently, patients with metastatic disease had limited treatment options, and their 5-year survival was approximately 20% [@b3-co16-s1-s45]. Moreover, tumours in [rcc]{.smallcaps} rarely responded to chemotherapy and radiotherapy [@b3-co16-s1-s45]. Cytokine therapy (interferon alfa or interleukin 2) had modest efficacy, with a response rate of 12% and a median survival of 13 months in a recent meta-analysis [@b4-co16-s1-s45]. However, since the development of molecularly targeted therapies ([Table [i]{.smallcaps}](#t1-co16-s1-s45){ref-type="table"}) that inhibit the pathways important in the pathogenesis of [rcc]{.smallcaps} ([Figure 1](#f1-co16-s1-s45){ref-type="fig"}), the outlook has improved.

2.. DISCUSSION
==============

2.1. Epidemiology and Biology of [rcc]{.smallcaps}
--------------------------------------------------

Loss of the von Hippel--Lindau ([vhl]{.smallcaps}) tumour suppressor is a pivotal event in both hereditary and sporadic [rcc]{.smallcaps} ([Figure 1](#f1-co16-s1-s45){ref-type="fig"}) [@b3-co16-s1-s45],[@b11-co16-s1-s45]. The resultant overactivity of the hypoxia-inducible factor ([hif]{.smallcaps}) pathway leads to overexpression of a set of hypoxia-related genes \[for example, vascular endothelial growth factor, platelet-derived growth factor B ([pdgfrb]{.smallcaps})\] and activation of a number of pathways \[for example, the phosphoinositide-3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (m[tor]{.smallcaps}) and *ras* signal transduction protein (Ras)/protein encoded by the murine leukemia viral oncogene homolog (Raf)/mitogen-activated protein kinase (Mek)/extracellular signal-regulated kinase (Erk) pathways\] [@b12-co16-s1-s45]. Signalling through m[tor]{.smallcaps} is present in most clear-cell [rcc]{.smallcaps} ^13,14.^ In addition to effects on tumour proliferation, angiogenesis, and apoptosis, activation of m[tor]{.smallcaps} may also potentiate the activity of [hif]{.smallcaps} [@b12-co16-s1-s45]. Inhibition of m[tor]{.smallcaps} results in tumour inhibition *in vitro* [@b13-co16-s1-s45] and *in vivo* [@b15-co16-s1-s45].

Interestingly, the epithelial growth factor receptor ([egfr]{.smallcaps}) pathway is also important to renal oncogenesis. Expression of [egfr]{.smallcaps} occurs at high frequency in [rcc]{.smallcaps} (70%--90%) [@b16-co16-s1-s45]--[@b18-co16-s1-s45], and loss of [vhl]{.smallcaps} causes increased expression of transforming growth factor α [@b19-co16-s1-s45] through [hif]{.smallcaps}-2α--dependent mechanisms [@b20-co16-s1-s45]--[@b22-co16-s1-s45]. Inhibition of this dysregulated autocrine loop is sufficient to reduce or abolish tumour growth in multiple [vhl]{.smallcaps}--/-- [rcc]{.smallcaps} cell lines [@b20-co16-s1-s45],[@b21-co16-s1-s45].

2.2. First-line Treatment with a Targeted Agent
-----------------------------------------------

Treatment with a number of targeted agents ([Table [i]{.smallcaps}](#t1-co16-s1-s45){ref-type="table"}) is now accepted as the standard of care in patients with metastatic [rcc]{.smallcaps}. In untreated patients, sunitinib [@b23-co16-s1-s45], temsirolimus [@b24-co16-s1-s45], and bevacizumab (when combined with interferon alfa) [@b25-co16-s1-s45] were all found to be superior to interferon alfa alone. For example, Motzer *et al.* and Cella *et al.* [@b23-co16-s1-s45],[@b26-co16-s1-s45] showed that patients treated with sunitinib experienced improved progression-free survival \[[pfs]{.smallcaps}: 11 months vs. 5 months; hazard ratio ([hr]{.smallcaps}): 0.42; 95% confidence interval ([ci]{.smallcaps}): 0.32 to 0.54; *p* \< 0.001), an improved objective response rate ([orr]{.smallcaps}: 31% vs. 6%; *p* \< 0.001), and improved quality of life. Similar benefits were also seen in patients who had received prior cytokine therapy [@b27-co16-s1-s45]. In that group, treatment with sorafenib was superior to placebo with regard to [pfs]{.smallcaps} (6 months vs. 3 months; [hr]{.smallcaps}: 0.44; 95% [ci]{.smallcaps}: 0.35 to 0.55; *p* \< 0.01) and the disease control rate (84% vs. 55%; *p* \< 0.001). Quality of life was also improved in patients receiving sorafenib as compared with those receiving placebo [@b28-co16-s1-s45]. Only the [egfr]{.smallcaps} inhibitors failed to deliver substantial therapeutic benefit, either as single agents [@b17-co16-s1-s45],[@b18-co16-s1-s45],[@b29-co16-s1-s45]--[@b31-co16-s1-s45] or in combination with agents such as bevacizumab [@b32-co16-s1-s45].

2.3. Second-line Treatment After Failure with a First-line Targeted Agent
-------------------------------------------------------------------------

Until recently, little evidence was available to guide therapy once patients had progressed on first-line treatment with a targeted agent. There is certainly a need to offer treatments to this patient population, not uncommonly encountered in clinical practice and often of appropriate performance status to tolerate more therapy. Re-treatment with another targeted agent has become commonplace practice despite the lack of prospective data [@b33-co16-s1-s45], and a number of retrospective studies have now been published about this approach ([Table [ii]{.smallcaps}](#t2-co16-s1-s45){ref-type="table"}). In all but two reports, the clinical benefit rate (complete response/partial response/stable disease) exceeded 50%, and in most cases, it reached 70% or better. In most reports, the median duration of benefit was 6 months or more. Re-treatment was generally well tolerated, with the most common grade 3 toxicities being fatigue, hypertension, and hand--foot syndrome.

Prior response to first-line targeted treatment did not predict response to second-line treatment [@b34-co16-s1-s45]--[@b37-co16-s1-s45]. As with other targeted therapies [@b38-co16-s1-s45], this lack of cross-resistance is thought to indicate incomplete suppression of tumour pathways with initial therapy. Further evidence of activity has been provided by the large prospective expanded-access programs of sorafenib 37 and sunitinib 39, which reported on 2488 and 2341 patients respectively. These programs showed that clinical benefit rates in these populations (84% and 52% respectively) were similar to those reported in phase iii trials. A substantial minority of patients previously exposed to targeted therapies also appeared to derive benefit from sunitinib and sorafenib in these programs.

The best evidence to date is provided by Motzer *et al*. [@b47-co16-s1-s45], who reported a positive phase [iii]{.smallcaps} trial in this clinical setting. Patients who had progressed on sunitinib or sorafenib (or both) were randomized to either the m[tor]{.smallcaps} inhibitor everolimus (10 mg orally, once daily) or to placebo. Although patients from all prognostic groups were enrolled into the trial, approximately half the patients had an intermediate prognosis. The primary endpoint was [pfs]{.smallcaps} as determined by independent reviewers. The trial was halted early when an interim analysis indicated a substantial and significant difference in [pfs]{.smallcaps} in favour of the everolimus group. The progression rate was 37% in the everolimus group as compared with 65% in the placebo group ([hr]{.smallcaps}: 0.30; 95% [ci]{.smallcaps}: 0.22 to 0.40; *p* \< 0.0001). Median [pfs]{.smallcaps} was 4.0 months (95% [ci]{.smallcaps}: 3.7 to 5.5 months) in the everolimus group as compared with 1.9 months (95% [ci]{.smallcaps}: 1.8 to 1.9 months) in the control group. Median overall survival ([os]{.smallcaps}) had not been reached in the everolimus arm (in excess of 10 months as compared with 8.8 months in the placebo group). The difference in [os]{.smallcaps} did not reach statistical significance, likely as a result of the planned crossover from placebo to everolimus on study. Although more stomatitis (40% vs. 8%), rash (25% vs. 4%), and fatigue (20% vs. 16%) occurred in the everolimus group, these side effects were mostly mild or moderate in severity. Pneumonitis (any grade) was detected in 22 patients in the everolimus group (8%), but only 8 patients [@b3-co16-s1-s45] had grade 3 pneumonitis. Quality of life was equivalent in both study arms.

At this time, everolimus can reasonably be considered to be the preferred second-line treatment after initial failure of sunitinib or sorafenib. Although [os]{.smallcaps} is always preferable as the primary endpoint in phase [iii]{.smallcaps} trials, the use of [pfs]{.smallcaps} in the Motzer study is an acceptable surrogate, and the overall case supporting the efficacy of everolimus as a second-line treatment is strong [@b48-co16-s1-s45]. Although everolimus is not yet approved in Canada for metastatic [rcc]{.smallcaps}, temsirolimus could be considered in this setting, given that it is currently approved in Canada and has a similar mechanism of activity. Once completed, two phase [iii]{.smallcaps} trials currently in progress may affect this choice. The first randomizes patients to temsirolimus or sorafenib as second-line therapy after progression on sunitinib (search for "NCT00474786" at [www.clinicaltrials.gov/ct2/search](www.clinicaltrials.gov/ct2/search)). The second randomizes patients who failed a previous systemic treatment, which may be a tyrosine kinase inhibitor, to either sorafenib or axitinib (search for "NCT00678392" at [www.clinicaltrials.gov/ct2/search](www.clinicaltrials.gov/ct2/search)).

3.. CONCLUSIONS
===============

Inhibitors of multiple kinases such as sunitinib and sorafenib are now established as standard first-line therapy in patients with [rcc]{.smallcaps}. When disease progression occurs after such therapy, there is clearly more benefit to be gained by re-treating these patients with another targeted agent. Everolimus is the drug of choice at the present time, and we expect it to obtain approval for this indication in Canada soon. Until such time as approval is forthcoming, temsirolimus (if available) could be substituted, given its similar mechanism of action. It would also not be unreasonable to use any of the targeted agents in [Table [ii]{.smallcaps}](#t2-co16-s1-s45){ref-type="table"} (if available) to treat patients with progressive [rcc]{.smallcaps} who have not previously been exposed to those agents. However, the benefits seen with rationally-developed targeted agents in the first-line setting strongly suggest that it is more appropriate to enrol those patients into clinical trials. Research priorities include the evaluation of predictive biomarkers to allow for patient enrichment, optimization of drug sequencing \[concurrent vs. sequential, and simultaneous blockade at several points of the same pathway (vertical blockade) vs. blockade of several collateral pathways (horizontal blockade)\], and identification of other effective drugs---for example, histone deacetylase [@b49-co16-s1-s45],[@b50-co16-s1-s45].

![Simplified schema of signalling pathways that contribute to renal oncogenesis. [vhl]{.smallcaps} = Von Hippel--Lindau tumour-suppressor protein; [egfr]{.smallcaps} = epidermal growth factor receptor; [hdac]{.smallcaps}= histone deacetylase; Hsp90 = heat shock protein 90; [hif]{.smallcaps} = hypoxia-inducible factor; [tgf]{.smallcaps}α = transforming growth factor α; [rtk]{.smallcaps}s = receptor tyrosine kinases; [igfr]{.smallcaps}-1 = insulin-like growth factor receptor 1; [vegf]{.smallcaps} = vascular endothelial growth factor; Raf = protein encoded by the murine leukemia viral oncogene homolog; Ras = ras signal transduction protein; [pi]{.smallcaps}3K = phosphoinositide-3-kinase; [mek]{.smallcaps} = mitogen-activated protein kinase; [pten]{.smallcaps} = protein encoded by the phosphatase and tensin homolog gene; [erk]{.smallcaps} = extracellular signal-regulated kinase; Akt = protein kinase B; m[tor]{.smallcaps} = mammalian target of rapamycin.](co16-s1-s45f1){#f1-co16-s1-s45}

###### 

Selected targeted agents in the treatment of renal cell carcinoma ([rcc]{.smallcaps})

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Name*                                                     *Targets*                                                                                            *Canadian regulatory status in [rcc]{.smallcaps}*
  ---------------------------------------------------------- ---------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------
  Tyrosine kinase inhibitors                                                                                                                                      

    Sunitinib[@b5-co16-s1-s45]\                              [vegfr]{.smallcaps} 1, 2, 3; [pdgfra]{.smallcaps}, [b]{.smallcaps}; Flt3; c-Kit; [ret]{.smallcaps}   Approved for patients with metastatic [rcc]{.smallcaps} of clear-cell histology and good or intermediate prognosis
     (Sutent[a](#tfn1-co16-s1-s45){ref-type="table-fn"})                                                                                                          

    Sorafenib [@b6-co16-s1-s45],[@b7-co16-s1-s45]\           Raf; [vegfr]{.smallcaps}2, 3; [pdgfrb]{.smallcaps}; Flt3; c-Kit; [ret]{.smallcaps}                   Approved for patients with locally advanced or metastatic [rcc]{.smallcaps} who have failed, or are intolerant to, cytokine therapy
     (Nexacar[b](#tfn2-co16-s1-s45){ref-type="table-fn"})                                                                                                         

    Temsirolimus [@b8-co16-s1-s45]\                          m[tor]{.smallcaps}                                                                                   Approved for patients with metastatic [rcc]{.smallcaps} (not funded in all provinces)
     (Torisel[c](#tfn3-co16-s1-s45){ref-type="table-fn"})                                                                                                         

    Axitinib[@b9-co16-s1-s45]\                               [vegfr]{.smallcaps}1, 2, 3; [pdgfra]{.smallcaps}, [b]{.smallcaps}; c-Kit                             Not approved
     (Pfizer[a](#tfn1-co16-s1-s45){ref-type="table-fn"})                                                                                                          

    Everolimus [@b8-co16-s1-s45]\                            m[tor]{.smallcaps}                                                                                   Under consideration
     (Certican[d](#tfn4-co16-s1-s45){ref-type="table-fn"})                                                                                                        

  Monoclonal antibodies                                                                                                                                           

    Bevacizumab [@b10-co16-s1-s45]\                          [vegf]{.smallcaps}                                                                                   Not approved
     (Avastin[e](#tfn5-co16-s1-s45){ref-type="table-fn"})                                                                                                         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Pfizer Canada, Kirkland, QC.

Bayer HealthCare AG, Leverkusen, Germany.

Wyeth, Madison, NJ, U.S.A.

Novartis Pharmaceuticals, St. Louis, MO, U.S.A.

Genentech, San Francisco, CA, U.S.A., and Hoffmann--La Roche Ltd., Mississauga, ON.

[vegfr]{.smallcaps} = vascular endothelial growth factor receptor; [pdgfra]{.smallcaps}, [b]{.smallcaps} = platelet-derived growth factor receptor α and B; Flt3 = fms-related tyrosine kinase 3; Raf = protein encoded by the murine leukemia viral oncogene homolog; m[tor]{.smallcaps} = mammalian target of rapamycin; [vegf]{.smallcaps} = vascular endothelial growth factor.

###### 

Retrospective data regarding the efficacy of second-line targeted therapy

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Reference*                                      *Pts (*n*)*   *Targeted treatment*                                                                                    *Clinical benefit*           *Benefit duration (months)*   *Frequency of grades 3 and 4 toxicities*                                  
  ------------------------------------------------ ------------- ------------------------------------------------------------------------------------------------------- ---------------------------- ----------------------------- ------------------------------------------ ------------------------------ --------------------------
  First-line sunitinib                                                                                                                                                                                                                                                                                        

    Sablin *et al.*, 2007 [@b40-co16-s1-s45]       22            Sunitinib                                                                                               Sorafenib                    70                            0/15/55                                    [pfs]{.smallcaps}: 6           [na]{.smallcaps}

    Sepulveda, *et al.*, 2008 [@b41-co16-s1-s45]   20            Sunitinib\                                                                                              Sorafenib                    70                            0/10/60                                    [ttp]{.smallcaps}: 7\          Fatigue (17%)\
                                                                 plus cytokines (100%)                                                                                                                                                                                         [os]{.smallcaps}: 9            Mucositis (9%)\
                                                                                                                                                                                                                                                                                                              Hypertension (9%)\
                                                                                                                                                                                                                                                                                                              [hfs]{.smallcaps} (9%)

    Dudek *et al.*, 2009 [@b42-co16-s1-s45]        20            Sunitinib\                                                                                              Sorafenib                    35                                                                       [ttp]{.smallcaps}: 2           [na]{.smallcaps}
                                                                 plus cytokines (80%)                                                                                                                                                                                                                         

  First-line sorafenib                                                                                                                                                                                                                                                                                        

    Sablin *et al.*, 2007 [@b40-co16-s1-s45]       68            Sorafenib                                                                                               Sunitinib                    73                            0/15/58                                    [pfs]{.smallcaps}: 7           [na]{.smallcaps}

    Eichelberg *et al.*, 2008 [@b43-co16-s1-s45]   30            Sorafenib\                                                                                              Sunitinib                    55                            0/11/44                                    [pfs]{.smallcaps}: 10          [hfs]{.smallcaps} (3%)\
                                                                 plus cytokines (67%)                                                                                                                                                                                                                         Leucopenia (3%)\
                                                                                                                                                                                                                                                                                                              Platelets (3%)

    Dudek *et al.*, 2009 [@b42-co16-s1-s45]        29            Sorafenib\                                                                                              Sunitinib                    59                            0/21/38                                    [ttp]{.smallcaps}: 5           [na]{.smallcaps}
                                                                 plus cytokines (55%)                                                                                                                                                                                                                         

  First-line sorafenib + sunitinib                                                                                                                                                                                                                                                                            

    Rini *et al.*, 2007 [@b44-co16-s1-s45]         62            Sorafenib (100%)\                                                                                       Axitinib                     55                            0/21/34                                                                   Fatigue (18%)\
                                                                 plus sunitinib (23%)\                                                                                                                                                                                                                        Hypertension (16%)\
                                                                 plus cytokines (60%)                                                                                                                                                                                                                         [hfs]{.smallcaps} (11%)

    Dutcher *et al.*, 2008 [@b45-co16-s1-s45]      59            Sorafenib\                                                                                              Axitinib                     100                           0/32/68                                    [pfs]{.smallcaps}: approx. 8   Fatigue (13%)\
                                                                 plus sunitinib (24%)\                                                                                                                                                                                                                        Hypertension (11%)\
                                                                 plus cytokines (64%)                                                                                                                                                                                                                         [hfs]{.smallcaps} (11%)

    Whorf *et al.*, 2008 [@b46-co16-s1-s45]        29            Sorafenib (*n*=12), sunitinib (*n*=15), both (*n*=2)                                                    Bevacizumab and everolimus   84                            0/19/65                                    [pfs]{.smallcaps}: 11          Proteinuria (17%)\
                                                                                                                                                                                                                                                                                                              Fatigue (7%)\
                                                                                                                                                                                                                                                                                                              Stomatitis (7%)

  First-line bevacizumab                                                                                                                                                                                                                                                                                      

    Knox *et al.*, 2007 [@b37-co16-s1-s45]         197           Bevacizumab\                                                                                            Sorafenib                    81                            0/3/78                                     [na]{.smallcaps}               [na]{.smallcaps}
                                                                 plus others (100%)                                                                                                                                                                                                                           

    Rini *et al.*, 2008[@b35-co16-s1-s45]          61            Bevacizumab\                                                                                            Sunitinib                    82                            0/23/59                                    [pfs]{.smallcaps}: 8\          Fatigue (34%)\
                                                                 plus others (66%)                                                                                                                                                                                             [os]{.smallcaps}: 12           Hypertension (18%)\
                                                                                                                                                                                                                                                                                                              [hfs]{.smallcaps} (10%)

  Other first-line                                                                                                                                                                                                                                                                                            

    Rini *et al.*, 2008 [@b36-co16-s1-s45]         37            Bevacizumab (*n*=15) or sunitinib (*n*=22) plus other\                                                  Sorafenib                    43                            0/3/40                                     [pfs]{.smallcaps}: 4           [hfs]{.smallcaps} (31%)\
                                                                 anti-angiogenics (13%) plus cytokines or others (72%)                                                                                                                                                                                        Fatigue (17%)\
                                                                                                                                                                                                                                                                                                              Hypertension (14%)

    Tamaskar *et al.*, 2008 [@b34-co16-s1-s45]     30            Miscellaneous (thalidomide, lenalidomide, bevacizumab, volociximab, AG13736, sorafenib, or sunitinib)   Sunitinib (*n*=16)           81                            0/56/25                                    [ttp]{.smallcaps}: 10          [na]{.smallcaps}

  Sorafenib (*n*=14)                               71            0/7/64                                                                                                                                                                                                                                       
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Pts = patients; [cr]{.smallcaps} = complete response; [pr]{.smallcaps} = partial response; [sd]{.smallcaps} = stable disease; [pfs]{.smallcaps} = progression-free survival; [na]{.smallcaps} = not available; [ttp]{.smallcaps} = time to progression; [os]{.smallcaps} = overall survival; [hfs]{.smallcaps} = hand--foot syndrome.

[^1]: Princess Margaret Hospital, Department of Medical Oncology and Hematology, University of Toronto, Toronto, ON.
